Newly-engineered angiopoietin-1 as a cell-priming agent for CVD

Area of Science:

• Regenerative Medicine
• Cardiovascular Research
• Biotechnology

Background:

• Peripheral blood stem cells (PBSC) show limited efficacy in ischemic cardiovascular disease (CVD) repair.
• Angiopoietin-1 (Ang1) enhances PBSC vasculogenic potential but faces production challenges.

Purpose of the Study:

• To engineer a novel Ang1 variant (FVA3-Ang1) for improved protein expression and efficacy.
• To evaluate the effect of FVA3-Ang1 on PBSC priming and their therapeutic potential in CVD models.

Main Methods:

• Engineered FVA3-Ang1 by incorporating VASP, COMP, FLAG sequences, and an influenza A virus (IAV) signal peptide.
• Assessed FVA3-Ang1 effects on endothelial cells and PBSC transcriptome.
• Tested FVA3-Ang1-primed PBSCs in mouse models of hind-limb ischemia and myocardial infarction.

Main Results:

• FVA3-Ang1 demonstrated enhanced endothelial cell activation compared to native Ang1.
• 24-hour FVA3-Ang1 priming shifted PBSC gene expression towards an endotheloid lineage.
• FVA3-Ang1-primed PBSCs exhibited superior engraftment and tissue regeneration in ischemic injury models.

Conclusions:

• Engineered FVA3-Ang1 overcomes limitations of native Ang1, enhancing PBSC therapeutic potential.
• FVA3-Ang1 priming represents a promising strategy for regenerative cardiovascular therapies.
• Clinical trials are initiated to assess FVA3-Ang1-primed PBSC efficacy and safety in CVD patients.